天士力(600535.SH):獲得藥物臨牀試驗批準通知書
格隆匯3月13日丨天士力(600535.SH)公佈,公司收到國家藥品監督管理局覈準簽發關於同種異體脂肪間充質基質細胞注射液(NR-20201)(稱“NR-20201注射液”)用於治療急性缺血性腦卒中的《藥物臨牀試驗批準通知書》。NR-20201注射液是公司自主研發的異體脂肪間充質基質細胞藥物,臨牀擬用適應症爲急性缺血性腦卒中的治療。臨牀前試驗結果表明該藥物可通過細胞歸巢機制,與血管內皮細胞發生協同作用,激活受損腦組織血管再生與功能修復。根據公開資料查詢,截至目前,全球範圍內尚無間充質基質細胞用於急性缺血性腦卒中類產品獲批上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.